APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lanreotide Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lanreotide Drugs Market Outlook and Growth Opportunities 2026

22 December 2025196 pages

Choose your research edition.

Industry ResearchLanreotide Drugs Industry Research Report 2026109 pages · $2,950 USDIndustry Growth & TrendsGlobal Lanreotide Drugs Industry Growth and Trends Forecast to 203278 pages · $3,450 USDMarket StructureGlobal Lanreotide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lanreotide Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Lanreotide Drugs Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Lanreotide Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lanreotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lanreotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lanreotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lanreotide Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lanreotide Drugs market include IPSEN. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Lanreotide Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lanreotide Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lanreotide Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Lanreotide Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Lanreotide Drugs Segment by Company

IPSEN

Lanreotide Drugs Segment by Type

90 mg

60 mg

120 mg

Lanreotide Drugs Segment by Application

Hospital

Pharmacy

Lanreotide Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lanreotide Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Lanreotide Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lanreotide Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Lanreotide Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lanreotide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lanreotide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lanreotide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Lanreotide Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lanreotide Drugs industry.

Chapter 3: Detailed analysis of Lanreotide Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Lanreotide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Lanreotide Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lanreotide Drugs Industry Trends Table 2. Lanreotide Drugs Industry Drivers Table 3. Lanreotide Drugs Industry Opportunities and Challenges Table 4. Lanreotide Drugs Industry Restraints Table 5. Global Lanreotide Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lanreotide Drugs Revenue Share by Company (2021-2026) Table 7. Global Lanreotide Drugs Sales Volume by Company (units) & (2021-2026) Table 8. Global Lanreotide Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Lanreotide Drugs Average Price (US$/unit) of Company (2021-2026) Table 10. Global Lanreotide Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Lanreotide Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Lanreotide Drugs Company, Product Type & Application Table 13. Global Lanreotide Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Lanreotide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 90 mg Table 18. Significant Companies of 60 mg Table 19. Significant Companies of 120 mg Table 20. Global Lanreotide Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 21. Global Lanreotide Drugs Sales Volume by Type (2021-2026) & (units) Table 22. Global Lanreotide Drugs Sales Volume by Type (2027-2032) & (units) Table 23. Global Lanreotide Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Lanreotide Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Lanreotide Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Lanreotide Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Lanreotide Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Lanreotide Drugs Sales Value Share by Type (2021-2026) Table 29. Global Lanreotide Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Pharmacy Table 32. Global Lanreotide Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 33. Global Lanreotide Drugs Sales Volume by Application (2021-2026) & (units) Table 34. Global Lanreotide Drugs Sales Volume by Application (2027-2032) & (units) Table 35. Global Lanreotide Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Lanreotide Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Lanreotide Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Lanreotide Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Lanreotide Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Lanreotide Drugs Sales Value Share by Application (2021-2026) Table 41. Global Lanreotide Drugs Sales Value Share by Application (2027-2032) Table 42. Global Lanreotide Drugs Sales by Region: 2021 VS 2025 VS 2032 (units) Table 43. Global Lanreotide Drugs Sales by Region (2021-2026) & (units) Table 44. Global Lanreotide Drugs Sales Market Share by Region (2021-2026) Table 45. Global Lanreotide Drugs Sales by Region (2027-2032) & (units) Table 46. Global Lanreotide Drugs Sales Market Share by Region (2027-2032) Table 47. Global Lanreotide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Lanreotide Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Lanreotide Drugs Sales Value Share by Region (2021-2026) Table 50. Global Lanreotide Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Lanreotide Drugs Sales Value Share by Region (2027-2032) Table 52. Global Lanreotide Drugs Market Average Price (US$/unit) by Region (2021-2026) Table 53. Global Lanreotide Drugs Market Average Price (US$/unit) by Region (2027-2032) Table 54. Global Lanreotide Drugs Sales by Country: 2021 VS 2025 VS 2032 (units) Table 55. Global Lanreotide Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Lanreotide Drugs Sales by Country (2021-2026) & (units) Table 57. Global Lanreotide Drugs Sales Market Share by Country (2021-2026) Table 58. Global Lanreotide Drugs Sales by Country (2027-2032) & (units) Table 59. Global Lanreotide Drugs Sales Market Share by Country (2027-2032) Table 60. Global Lanreotide Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Lanreotide Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Lanreotide Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Lanreotide Drugs Sales Value Market Share by Country (2027-2032) Table 64. IPSEN Company Information Table 65. IPSEN Business Overview Table 66. IPSEN Lanreotide Drugs Sales (units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. IPSEN Lanreotide Drugs Product Portfolio Table 68. IPSEN Recent Development Table 69. Key Raw Materials Table 70. Raw Materials Key Suppliers Table 71. Lanreotide Drugs Distributors List Table 72. Lanreotide Drugs Customers List Table 73. Research Programs/Design for This Report Table 74. Authors List of This Report Table 75. Secondary Sources Table 76. Primary Sources List of Figures Figure 1. Lanreotide Drugs Product Image Figure 2. Global Lanreotide Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lanreotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Lanreotide Drugs Sales (2021-2032) & (units) Figure 5. Global Lanreotide Drugs Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Lanreotide Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 90 mg Image Figure 10. 60 mg Image Figure 11. 120 mg Image Figure 12. Global Lanreotide Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 13. Global Lanreotide Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Lanreotide Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Lanreotide Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Lanreotide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Lanreotide Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Pharmacy Image Figure 20. Global Lanreotide Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 21. Global Lanreotide Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Lanreotide Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Lanreotide Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Lanreotide Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Lanreotide Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Lanreotide Drugs Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 27. Global Lanreotide Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Lanreotide Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Lanreotide Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Lanreotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Lanreotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Lanreotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Lanreotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Lanreotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Lanreotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Lanreotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Lanreotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Lanreotide Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Lanreotide Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Lanreotide Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Lanreotide Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Lanreotide Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 90 mg
  • 60 mg
  • 120 mg
Applications
  • Hospital
  • Pharmacy
Companies covered
  • IPSEN

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Lanreotide Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Lanreotide Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Lanreotide Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Lanreotide Drugs Market Dynamics
  1. 2.1 Lanreotide Drugs Industry Trends
  2. 2.2 Lanreotide Drugs Industry Drivers
  3. 2.3 Lanreotide Drugs Industry Opportunities and Challenges
  4. 2.4 Lanreotide Drugs Industry Restraints
3 Lanreotide Drugs Market by Company
  1. 3.1 Global Lanreotide Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Lanreotide Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Lanreotide Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Lanreotide Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Lanreotide Drugs Company Ranking (2024-2026)
  6. 3.6 Global Lanreotide Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Lanreotide Drugs Company Product Type and Application
  8. 3.8 Global Lanreotide Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Lanreotide Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Lanreotide Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Lanreotide Drugs Market by Type
  1. 4.1 Lanreotide Drugs Type Introduction
  2. 4.1.1 90 mg
  3. 4.1.2 60 mg
  4. 4.1.3 120 mg
  5. 4.2 Global Lanreotide Drugs Sales Volume by Type
  6. 4.2.1 Global Lanreotide Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Lanreotide Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Lanreotide Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Lanreotide Drugs Sales Value by Type
  10. 4.3.1 Global Lanreotide Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Lanreotide Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Lanreotide Drugs Sales Value Share by Type (2021-2032)
5 Lanreotide Drugs Market by Application
  1. 5.1 Lanreotide Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.2 Global Lanreotide Drugs Sales Volume by Application
  5. 5.2.1 Global Lanreotide Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lanreotide Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Lanreotide Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Lanreotide Drugs Sales Value by Application
  9. 5.3.1 Global Lanreotide Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Lanreotide Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Lanreotide Drugs Sales Value Share by Application (2021-2032)
6 Lanreotide Drugs Regional Sales and Value Analysis
  1. 6.1 Global Lanreotide Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lanreotide Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Lanreotide Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Lanreotide Drugs Sales by Region (2027-2032)
  5. 6.3 Global Lanreotide Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Lanreotide Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Lanreotide Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Lanreotide Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Lanreotide Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Lanreotide Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Lanreotide Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Lanreotide Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Lanreotide Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Lanreotide Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Lanreotide Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Lanreotide Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Lanreotide Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Lanreotide Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Lanreotide Drugs Sales Value Share by Country, 2025 VS 2032
7 Lanreotide Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Lanreotide Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lanreotide Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Lanreotide Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Lanreotide Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Lanreotide Drugs Sales by Country (2027-2032)
  6. 7.4 Global Lanreotide Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Lanreotide Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Lanreotide Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Lanreotide Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Lanreotide Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Lanreotide Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 IPSEN
  2. 8.1.1 IPSEN Company Information
  3. 8.1.2 IPSEN Business Overview
  4. 8.1.3 IPSEN Lanreotide Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 IPSEN Lanreotide Drugs Product Portfolio
  6. 8.1.5 IPSEN Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Lanreotide Drugs Value Chain Analysis
  2. 9.1.1 Lanreotide Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Lanreotide Drugs Sales Mode & Process
  6. 9.2 Lanreotide Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Lanreotide Drugs Distributors
  9. 9.2.3 Lanreotide Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst